James (Josh) Wilson, a securities litigation partner at Faruqi & Faruqi, LLP, encourages investors who suffered losses in excess of $100,000 in UnitedHealth to contact him directly to discuss their options.
If you suffered losses greater than $100,000 investing in UnitedHealth stock or options between March 14, 2022 and February 27, 2024 and I would like to discuss your legal rights, call Faruqi and Faruqi team up Josh Wilson directly in 877-247-4292 either 212-983-9330 (Extension 1310)You can also click here for additional information: www.faruqilaw.com/UNH.
NEW YORK, July 04, 2024 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against UnitedHealth Group Incorporated (NYSE:) (UnitedHealth or the Company) (NYSE: UNH) and reminds investors Deadline: July 15, 2024 to seek the role of lead plaintiff in a federal securities class action lawsuit that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California, and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) UnitedHealth never established adequate firewalls between Optum and UnitedHealthcare as required by its own policy, and as it told the court in the antitrust action, the Department of Justice, and investors it would do; (2) The firewalls were never adequately created for certain business applications; (3) Despite assurances to the contrary, there was never a meaningful technological separation between Optum and UnitedHealthcare that would prevent the sharing of confidential customer information; and (4) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
On February 27, 2024, The Wall Street Journal reported that the U.S. Department of Justice (“DOJ”) had launched an investigation into UnitedHealth, examining the relationships between the company’s UnitedHealthcare insurance unit and its Optum health services division, which owns physician groups, among other assets.
Following this news, UnitedHealth’s stock price fell $27.04, or 5.1%, over two consecutive trading days to close at $498.28 per share on February 28, 2024, thereby harming investors.
The Court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class, who is proper and typical of class members, who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may ask the Court to serve as lead plaintiff through counsel of his or her choice, or may choose to do nothing and remain an absent class member. His or her ability to share in any recovery is not affected by the decision whether or not to serve as lead plaintiff.
Faruqi & Faruqi, LLP also encourages anyone with information regarding UnitedHealth’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
For more information about the United health class action lawsuit, go to www.faruqilaw.com/UNH either call Faruqi and Faruqi team up Josh Wilson directly in 877-247-4292 either 212-983-9330 (Extension 1310).
Follow us for updates on LinkedIn, X or Facebook (NASDAQ:).
Attorney Advertisement. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Past results do not guarantee or predict a similar outcome with respect to any future matter. We appreciate the opportunity to discuss your particular case. All communications will be treated confidentially.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5e848124-9c14-4bab-ba13-256ecec0c433